The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors

Abstract excerpt

INTRODUCTION: The risk of over-treatment in low-advanced PTC stages has prompted clinicians to search for new reliable prognostic factors. The presence of BRAF mutation, the most frequent molecular event in PTC, seems to be a good candidate. However, there is still lack of randomised trials and its significance has been proved by retrospective analyses, involving a large group of patients. The question arises...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Thyroid and Parathyroid Surgery
• Share to Thyroid Cancer Diagnosis and Treatment
• Share to Thyroid Disorders and Treatments